CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
Pirfenidonedrug
Likely dose
Pirfenidone 2403 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03208933
NCT03208933Phase 3Completed
CompareCT.gov

Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice

Hoffmann-La Roche·interventional·Posted Jul 6, 2017·Updated Nov 20, 2020

In Brief

A Phase 3 clinical trial evaluating Pirfenidone for Idiopathic Pulmonary Fibrosis. Completed, enrolled 60 participants across 11 sites.

Detailed Summary

This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJul 6, 2017
Enrollment StartOct 23, 2017
Primary CompletionNov 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.0 years ago

Interventions

Pirfenidonedrug

Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.